BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-31@catalystbrief.girapphe.com
DTSTAMP:20261117T061548Z
LAST-MODIFIED:20261117T061548Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Readout: Hoffmann-La Roche — Afimkibart [Jan 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Assess the Efficacy and 
 Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenan
 ce Therapy in Participants With Moderately to Severely Active Ulcerative C
 olitis.\nSource: https://clinicaltrials.gov/study/NCT06589986\nhttps://cat
 alystbrief.girapphe.com/e/31?lang=en\nNot investment advice. Dates may cha
 nge.
URL:https://catalystbrief.girapphe.com/e/31?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
